Fig. 2


Immunophenotyping of NK cell subpopulations. Percentages of a CD56+/CD69+ NKT/NK cells, b CD3−/CD56+ NK cells, c CD3−/CD94+ NK cells, d CD3−/NKG2D+ NK cells, e CD3−/NKp30+ NK cells, f CD3−/NKp46+ NK cells in healthy controls (Ctrl, n = 22), non-recurrent (n = 23) and recurrent patients (n = 9) with SCCHN before (t0), after application of 20–30 Gy (t1), 3 months (t2), 6 months (t3) after treatment and at time of locoregional recurrence (t5, 3–15 months after t0). The data show mean values ± standard deviation of the percentage of positively stained cells. Significances are illustrated between t0 and other time points (tx) after start of RCT as well as between controls (Ctrl) and all time points of RCT (*p ≤ 0.05; **p ≤ 0.01; ***p ≤ 0.001)